CureVac NV
NASDAQ:CVAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Y
|
Yong Tai Bhd
KLSE:YONGTAI
|
MY |
CureVac NV
Accrued Liabilities
CureVac NV
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Accrued Liabilities
€26.7m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Accrued Liabilities
€22.5m
|
CAGR 3-Years
75%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Accrued Liabilities
€3.1m
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Accrued Liabilities?
Accrued Liabilities
26.7m
EUR
Based on the financial report for Dec 31, 2024, CureVac NV's Accrued Liabilities amounts to 26.7m EUR.
What is CureVac NV's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
17%
Over the last year, the Accrued Liabilities growth was -46%. The average annual Accrued Liabilities growth rates for CureVac NV have been -17% over the past three years , 17% over the past five years .
